Recent Company News

• 09:04 AM ET Jun 09, 2026
  

  UCB notes BIMZELX (bimekizumab injection) receives positive reimbursement recommendation from Canada's drug agency for Hidradenitis Suppurativa (€260.80, -0.20)

• 09:19 AM ET Jun 08, 2026
  

  Transcript Intelligence: UCB Capital Markets Day

• 01:02 AM ET Jun 05, 2026
  

  UCB announces new EULAR 2026 data show CIMZIA (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels (€259.50, 0.00)

• 02:51 AM ET Jun 01, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:04 AM ET Jun 04, 2026
  

  UCB présente des données sur le dapirolizumab pegol lors de l’EULAR 2026 (€251.90, 0.00)

• 01:04 AM ET Jun 04, 2026
  

  UCB presents data on dapirolizumab pegol at EULAR 2026 (€251.90, 0.00)

• 01:02 AM ET Jun 03, 2026
  

  UCB announces BIMZELX (bimekizumab) data at EULAR 2026 in PsA and axSpA (€248.30, 0.00)

• 01:07 AM ET Jun 02, 2026
  

  UCB completes Neurona Therapeutics acquisition (€254.20, 0.00)